7 Mar 2017
New drug combination targets aggressive blood cancer
Safety and efficacy of combining talazoparib with decitabine to treat acute myeloid leukemia (AML) are subject of multi-site clinical trial GRAND RAPIDS,...Read More
30 Dec 2016
What difference does a year make?
When it comes to biomedical research and science education, a year can make all the difference. In 2016, we celebrated Van Andel...Read More
6 Oct 2016
Van Andel Research Institute–Stand Up To Cancer Epigenetics Dream Team Symposium
The inaugural Van Andel Research Institute–Stand Up To Cancer Epigenetics Dream Team symposium reflects the collaborative spirit of the team by bringing...Read More
28 Jan 2016
Phase II colorectal cancer clinical trial first to receive support, scientific oversight from Van Andel Research Institute–Stand Up To Cancer Epigenetics Dream Team
GRAND RAPIDS, Mich. (Jan. 28, 2016)—The first clinical trial to move forward as part of the Van Andel Research Institute–Stand Up To...Read More
26 Feb 2015
Van Andel Research Institute appoints leading cancer scientist Dr. Stephen Baylin as professor
GRAND RAPIDS, Mich. (Feb. 26, 2015)—Renowned cancer scientist and epigenetics expert Stephen Baylin, M.D., has accepted an appointment at Van Andel Research Institute...Read More
20 Oct 2014
Stand Up To Cancer Epigenetics Dream Team continues with $7.5 million funding from Van Andel Research Institute
Grand Rapids, Michigan (October 20, 2014)— The work of one of the Stand Up To Cancer (SU2C) inaugural Dream Teams, launched in...Read More